Baofeng Guo
Changchun, 130033, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Histone acetyltransferase Kat2a regulates glioma stem cell differentiation via Hsp90aa1-dependent oxidative phosphorylation.
Journal: Biochemical pharmacology
Published: May 16, 2026
Taxifolin promotes glioma stem cell differentiation via CYP1B1-mediated EMT suppression.
Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology
Published: March 09, 2025
A scientometric analysis of immunotherapies for gliomas: Focus on GBM.
Journal: Asian journal of surgery
Published: September 20, 2023
Taxifolin inhibits melanoma proliferation/migration impeding USP18/Rac1/JNK/β-catenin oncogenic signaling.
Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology
Published: May 11, 2023
RSL3 triggers glioma stem cell differentiation via the Tgm2/AKT/ID1 signaling axis.
Journal: Biochimica et biophysica acta. Molecular basis of disease
Published: June 03, 2022
Epigenetic regulation of cancer stem cells: Shedding light on the refractory/relapsed cancers.
Journal: Biochemical pharmacology
Published: March 31, 2022
Roles for the methyltransferase SETD8 in DNA damage repair.
Journal: Clinical epigenetics
Published: September 13, 2021
RSL3 enhances the antitumor effect of cisplatin on prostate cancer cells via causing glycolysis dysfunction.
Journal: Biochemical pharmacology
Published: June 10, 2021
GRIM-19 inhibits proliferation and induces apoptosis in a p53-dependent manner in colorectal cancer cells through the SIRT7/PCAF/MDM2 axis.
Journal: Experimental cell research
Published: June 06, 2021
Corrigendum to "RGFP966, a histone deacetylase 3 inhibitor, promotes glioma stem cell differentiation by blocking TGF-β signaling via SMAD7" [Biochem. Pharmacol. 180 (2020) 114118].
Journal: Biochemical pharmacology
Published: October 11, 2020
RGFP966, a histone deacetylase 3 inhibitor, promotes glioma stem cell differentiation by blocking TGF-β signaling via SMAD7.
Journal: Biochemical pharmacology
Published: April 10, 2020
A Combination of BRD4 and HDAC3 Inhibitors Synergistically Suppresses Glioma Stem Cell Growth by Blocking GLI1/IL6/STAT3 Signaling Axis.
Journal: Molecular cancer therapeutics
Published: February 17, 2020
Showing 1-12 of 12
Last Updated: 09/26/2026